The estimated Net Worth of Venture Partners Vi Lpovp V... is at least $6.16 Milhão dollars as of 2 September 2014. Venture V owns over 35,000 units of Nanostring Technologies Inc stock worth over $177,331 and over the last 11 years Venture sold NSTG stock worth over $5,981,793.
Venture has made over 5 trades of the Nanostring Technologies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture sold 35,000 units of NSTG stock worth $390,250 on 2 September 2014.
The largest trade Venture's ever made was selling 166,755 units of Nanostring Technologies Inc stock on 11 June 2014 worth over $2,514,665. On average, Venture trades about 51,352 units every 11 days since 2013. As of 2 September 2014 Venture still owns at least 1,684,054 units of Nanostring Technologies Inc stock.
You can see the complete history of Venture V stock trades at the bottom of the page.
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus..., eNicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Nanostring Technologies Inc executives and other stock owners filed with the SEC include: